Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK2223 in Relapsed or Refractory T-cell Non Hodgkin Lymphoma
NCT07192471Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of KK2223 in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Incidence of treatment-emergent adverse events at 1.5 years and Maximum tolerated dose at 1.5 years. Started Sep 2026; status: recruiting.
02
Drugs
KK2223
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07192471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192471.